Using our proprietary Genomic RNA Packaging Enhancement (GRPE) and delivery technologies, our platform allows for a highly efficient VLP packaging process and enables the incorporation of designer molecules to modulate immune responsiveness and cell function.  SHC Therapeutics is uniquely positioned to develop personalized and precision biotherapeutics across a broad range of disease areas and has a lead candidate at the pre-clinical phase based on our core technology.

HIV

EBV

Zoster